Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Earnings for Instil Bio, Inc. (TIL)
Earnings in 2023 (TTM): $-156,087,000
According to Instil Bio, Inc.'s latest financial reports the company's current earnings (TTM) are $-156,087,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Instil Bio, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-156,087,000 | $-156,087,000 |
| 2022 | $-225,250,000 | $-223,177,000 |
| 2021 | $-156,755,000 | $-156,794,000 |
| 2020 | $-37,587,000 | $-37,738,000 |
| 2019 | $-6,522,000 | $-6,454,000 |